Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC EBITDA Margin

EBITDA as a percentage of revenue.

Century Therapeutics, Inc.NASDAQ: IPSC

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 2334.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -706.5% for the fiscal year ending Dec 2026, down from 3.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
3.2%+1695.0 pp YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1695.0 pp-709.7 pp-2404.6 pp
3 years+2334.4 pp-2010.7 pp-4345.1 pp
5 years-54.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
3.2%
Year-over-year change
+1695.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's FY2025 EBITDA Margin of 3.2% is the highest of the 5 companies compared; the peer median is -433.5%.
  • Its year-over-year change of +1695.0 pp is the 2nd highest of 5, against a peer median of +166.4 pp.
  • Over three fiscal years its change of +2334.4 pp compares with a peer median of +1980.3 pp.
IPSC Competitors Peer median
EBITDA Margin for IPSC and competitors
Company Period LTM level YoY 3-year change
IPSCCentury Therapeutics, Inc.FY20253.2% +1695.0 pp+2334.4 pp
CUECue Biopharma, Inc.LTM Mar 2026-48.4% +416.8 pp+3974.4 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026-97.9% -84.1 pp-13.9 pp
COEPCoeptis Therapeutics, Inc.LTM Mar 2026-769.0% +15034.6 pp—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18634.1% -28166.9 pp—
EQEquillium, Inc.FY2025— ——
TELOTelomir Pharmaceuticals, Inc. Common StockFY2025— ——
OSTXOS Therapies IncorporatedFY2025— ——
Peer median (excluding IPSC) -433.5%+166.4 pp+1980.3 pp

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue05.2M2.24M6.59M109.16M
Cost of Revenue4.58M00013.1M
Gross Profit(4.58M)5.2M2.24M6.59M96.06M
Gross Margin—100.0%100.0%100.0%88.0%
Research & Development75.65M97.17M92.71M107.24M95.67M
Selling, General & Admin14.65M31.86M34.71M33.16M24M
Operating Expenses90.3M139.03M148.78M144.73M111.1M
Depreciation & Amortization4.58M8.44M13.04M13.3M13.1M
EBITDA(89.92M)(121.2M)(121.21M)(111.47M)3.45M
EBITDA Margin—-2331.2%-5423.2%-1691.8%3.2%
Operating Income(94.88M)(133.83M)(146.55M)(138.14M)(15.04M)
Operating Margin—-2574.2%-6556.9%-2096.5%-13.8%
Interest Income898K2.99M12.68M13.01M7.35M
Interest Expense1.28M0540K00
Other Income / Expenses(898K)2.99M11.75M13.36M5.39M
Income Before Tax(95.78M)(130.84M)(134.79M)(124.78M)(9.65M)
Pre-Tax Margin—-2516.7%-6031.0%-1893.7%-8.8%
Income Tax Expense43K91K1.88M1.79M(68K)
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Net Margin—-2518.4%-6115.1%-1920.9%-8.8%
EPS (Basic)(1.74)(2.27)(2.30)(1.61)(0.11)
EPS (Diluted)(1.74)(2.27)(2.30)(1.61)(0.11)
Weighted Avg Shares55.01M57.76M59.31M78.65M86.56M
Weighted Avg Shares (Diluted)55.01M57.76M59.31M78.65M86.56M

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.